Our demonstration of JAK-STAT hyperactivation under C9ORF72 deficient conditions may further explain the relatively high occurrence of autoimmune diseases in ALS/FTLD patients with C9ORF72 mutations16 and support the inhibition of the JAK/STAT pathway as a valid therapeutic approach to treat these patients. The gene discussed is SOAT1; the disease is amyotrophic lateral sclerosis.